<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">HET</journal-id>
<journal-id journal-id-type="hwp">sphet</journal-id>
<journal-id journal-id-type="nlm-ta">Hum Exp Toxicol</journal-id>
<journal-title>Human &amp; Experimental Toxicology</journal-title>
<issn pub-type="ppub">0960-3271</issn>
<issn pub-type="epub">1477-0903</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0960327112455670</article-id>
<article-id pub-id-type="publisher-id">10.1177_0960327112455670</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The role of adenosine receptors on amitriptyline-induced electrophysiological changes on rat atrium</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kalkan</surname>
<given-names>S</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112455670">1</xref>
<xref ref-type="corresp" rid="corresp1-0960327112455670"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oransay</surname>
<given-names>K</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112455670">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bal</surname>
<given-names>IB</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327112455670">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ertunc</surname>
<given-names>M</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327112455670">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sara</surname>
<given-names>Y</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327112455670">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Iskit</surname>
<given-names>AB</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327112455670">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0960327112455670">
<label>1</label>Department of Pharmacology, School of Medicine, Dokuz Eylul University, Inciralti, Izmir, Turkey</aff>
<aff id="aff2-0960327112455670">
<label>2</label>Department of Pharmacology, Faculty of Medicine, Hacettepe University, Sıhhıye, Ankara, Turkey</aff>
<author-notes>
<corresp id="corresp1-0960327112455670">Sules Kalkan, Professor in Pharmacology, Department of Pharmacology, School of Medicine, Dokuz Eylul University, Inciralti, Izmir 35340, Turkey Email: <email>sule.kalkan@deu.edu.tr</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>32</volume>
<issue>1</issue>
<fpage>62</fpage>
<lpage>69</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>We investigated the role of adenosine receptors in amitriptyline-induced cardiac action potential (AP) changes in isolated rat atria. In the first group, APs were recorded after cumulative addition of amitriptyline (1 μM, 10 μM and 50 μM). In other groups, each atrium was incubated with selective adenosine A<sub>1</sub> antagonist (8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 10<sup>−4</sup> M) or selective adenosine A<sub>2a</sub> receptor antagonist (8-(3-chlorostyryl) caffeine, 10<sup>−5</sup> M) before amitriptyline administration. Resting membrane potential, AP amplitude (APA), AP duration at 50% and 80% of repolarization (APD<sub>50</sub> and APD<sub>80</sub>, respectively), and the maximum rise and decay slopes of AP were recorded. Amitriptyline (50 μM) prolonged the APD<sub>50</sub> and APD<sub>80</sub> (<italic>p</italic> &lt; 0.001) and the maximum rise slope of AP was reduced by amitriptyline (<italic>p</italic> &lt; 0.0001). Amitriptyline reduced maximum decay slope of AP only at 50 μM (<italic>p</italic> &lt; 0.01). DPCPX significantly decreased the 50-μM amitriptyline-induced APD<sub>50</sub> and APD<sub>80</sub> prolongation (<italic>p</italic> &lt; 0.001). DPCPX significantly prevented the effects of amitriptyline (1 μM and 50 μM) on maximum rise slope of AP (<italic>p</italic> &lt; 0.05). DPCPX significantly prevented the amitriptyline-induced (50 μM) reduction in maximum decay slope of AP (<italic>p</italic> &lt; 0.001). The selective adenosine A<sub>1</sub> receptor antagonist prevented the electrophysiological effects of amitriptyline on atrial AP. A<sub>1</sub> receptor stimulation may be responsible for the cardiovascular toxic effects produced by amitriptyline.</p>
</abstract>
<kwd-group>
<kwd>Amitriptyline</kwd>
<kwd>adenosine receptor antagonists</kwd>
<kwd>cardiac action potential</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0960327112455670">
<title>Introduction</title>
<p>The manifestations of tricyclic antidepressant (TCA) toxicity are mainly of cardiovascular origin including cardiac conduction abnormalities, dysrhythmias and hypotension. Cardiovascular toxicity is primarily responsible for the morbidity and mortality attributed to TCAs. Sinus tachycardia is the most common dysrhythmia associated with TCA toxicity and usually does not cause hemodynamic compromise. Ventricular tachycardia is the most common lethal ventricular dysrhythmia. Clinical observational data concerning QRS (&gt;100 msec) and QT (&gt;450 msec) prolongation suggest that the ventricular tachyarrhythmias are induced by TCAs. The blockade of cardiac Na<sup>+</sup> and K<sup>+</sup> channels is the primary mechanism responsible for arrhythmias.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112455670">1</xref>
</sup>
</p>
<p>Opipramol and amitriptyline are the most common agents of TCA poisonings in Turkey.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112455670">2</xref>
</sup> In our previous study, we demonstrated that amitriptyline-induced QRS prolongation and hypotension were reversed by the blockade of adenosine A<sub>1</sub> and A<sub>2a</sub> receptors with specific antagonists like 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; selective A<sub>1</sub> receptor antagonist) and 8-(3-chlorostyryl) caffeine (CSC; selective A<sub>2a</sub> receptor antagonist). Furthermore, pretreatment with these antagonists also prevented the development of amitriptyline-induced QRS prolongation and hypotension.<sup>
<xref ref-type="bibr" rid="bibr3-0960327112455670">3</xref>
</sup> Additionally, the adenosine A<sub>1</sub> receptor antagonist, DPCPX, was found to shorten the QRS prolongation induced by amitriptyline in an isolated rat heart model.<sup>
<xref ref-type="bibr" rid="bibr4-0960327112455670">4</xref>,<xref ref-type="bibr" rid="bibr5-0960327112455670">5</xref>
</sup> These results showed that adenosine A<sub>1</sub> receptor stimulation and/or endogenous adenosine may have a role in amitriptyline-induced QRS prolongation.</p>
<p>Adenosine is a potent extracellular messenger in cardiac tissue, where it induces negative inotropic and chronotropic effects, reduces conduction in the sinoatrial and atrioventricular (AV) nodes and modulates response to beta adrenergic stimulation through adenosine receptors. The regulatory actions of adenosine are mediated via four subtypes of the receptor described as A<sub>1</sub>, A<sub>2a</sub>, A<sub>2b</sub> and A<sub>3</sub>. The heart contains predominantly A<sub>1</sub> adenosine receptors. Adenosine A<sub>1</sub> receptor-mediated actions in heart are either cyclic adenosine monophosphate (cAMP)-independent (direct effects) or c-AMP-dependent (indirect or anti-adrenergic effects).<sup>
<xref ref-type="bibr" rid="bibr6-0960327112455670">6</xref>,<xref ref-type="bibr" rid="bibr7-0960327112455670">7</xref>
</sup>
</p>
<p>In the present study, we investigated the role of adenosine receptors in amitriptyline-induced electrophysiological changes in isolated rat atria.</p>
</sec>
<sec id="section2-0960327112455670" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-0960327112455670">
<title>Animals</title>
<p>Adult male Wistar rats, weighing 250–280 g, were obtained from the animal facility of Hacettepe University and were housed under environmentally controlled conditions at 21 ± 2°C with 12 h dark/12 h light illumination sequence (the lights were on between 07:00 and 19:00) with food and water ad libitum. The <italic>Guiding Principles in the Care and Use of Laboratory Animals</italic> together with The Recommendations from the Declaration of Helsinki were strictly adhered during execution of all procedures. This project was approved by the Animal Care and Use Committee of Dokuz Eylul University, School of Medicine, Izmir, Turkey (Protocol number: 55/2007). Experiments were performed at Hacettepe University, Faculty of Medicine, Department of Pharmacology.</p>
</sec>
<sec id="section4-0960327112455670">
<title>Chemicals</title>
<p>Amitriptyline was obtained from Merck Chemical Company (Darmstadt, Germany), DPCPX (a selective A<sub>1</sub> receptor antagonist) and CSC (a selective A<sub>2a</sub> receptor antagonist) were purchased from Sigma Chemical Company (St Louis, Missouri, USA). Dimethyl sulfoxide (DMSO) was obtained from Aldrich Chemical (St Louis, Missouri, USA). Amitriptyline was dissolved in distilled water (stock concentration of 0.01 M). Both DPCPX and CSC were dissolved in DMSO. All adenosine antagonists were prepared at stock concentrations of 10<sup>−2</sup> M (in 10% DMSO).</p>
<sec id="section5-0960327112455670">
<title>Recording of cardiac APs</title>
<p>Rats were anesthetized with diethyl ether and then their hearts were quickly removed. Atrial action potentials (APs) were recorded by conventional microelectrode tecnique. Right and left atria were carefully dissected and immediately mounted in a 10-ml perfusion chamber. The superfusing Tyrode solution (5 mL/min) was oxygenated with a gas mixture of 5% CO<sub>2</sub> and 95% O<sub>2</sub> and kept at 37°C by a temperature-controlled circulator. The composition of the Tyrode solution was (in millimoles per liter) given as follows: NaCl: 137 mM/L, KCl: 4 mM/L, CaCl<sub>2</sub>: 1.8 mM/L, MgCl<sub>2</sub>: 0.5 mM/L, Na<sub>2</sub>HPO<sub>4</sub>: 1 mM/L, NaHCO<sub>3</sub>: 12 mM/L and glucose: 5.0 mM/L at pH 7.4. Borosilicate glass micropipettes were prepared using a vertical pipette puller (Model 700C, David Kopf Instruments, USA). The tip resistances of pipettes were 30–50 MΩ when filled with 3 M KCl. The atria were electrically driven using a pair of platinum electrodes placed under the tissue. A 2-ms duration and 1-Hz frequency square-wave pulses were delivered from a stimulator (Grass S88, Grass Instruments, Missouri, USA).<sup>
<xref ref-type="bibr" rid="bibr8-0960327112455670">8</xref>
</sup> AP signals were amplified by Axoclamp-2A (Axon Instruments, Foster City, California, USA) and displayed on a digitized oscilloscope (Tektronix, Wilsonville, Oregon, USA). Data were recorded by PowerLab and analyzed by Scope 3.7 software (ADI Instruments, Sydney, Australia). The variables measured were resting membrane potential (RMP), AP amplitude (APA), AP duration at 50% and 80% of repolarization (APD<sub>50</sub> and APD<sub>80</sub>, respectively) levels and maximum rise and decay slopes of AP.<list list-type="simple">
<list-item>
<p>RMP: During resting, membrane potential is mainly determined by the K<sup>+</sup> equilibrium potential.</p>
</list-item>
<list-item>
<p>APA: AP amplitude is related with voltage-dependent Na<sup>+</sup> channel activity.</p>
</list-item>
<list-item>
<p>Prolongation of APD<sub>50</sub> or APD<sub>80</sub> is due to the reduced K<sup>+</sup> channel activity and shortens when the K<sup>+</sup> channel activity is increased.</p>
</list-item>
<list-item>
<p>Maximum rise of AP is a measure of voltage-dependent Na<sup>+</sup> recruitment. Decay slope of AP is correlated with delayed rectifier K<sup>+</sup> channel activity.</p>
</list-item>
</list>Each atrium was used once for testing a single drug. We used the average of AP values recorded from 12 cells for each atrium. The ‘<italic>n</italic>’ is the number of atrium and also is the number of rats. The baseline values of AP were recorded from each atrium at the beginning of the experimental protocol. In all rats, initial values of AP were pooled to be used as the control value.</p>
</sec>
</sec>
<sec id="section6-0960327112455670">
<title>Drug administration</title>
<p>Rats were randomly allocated into the following three groups.</p>
<sec id="section7-0960327112455670">
<title>Group 1 (three animals, 12 cells for each dose)</title>
<p>In this group, we evaluated the electrophysiological effects of amitriptyline in rat atria. Cumulative concentration–response curves were obtained by stepwise increased concentrations of amitriptyline (1 μM, 10 μM and 50 μM). The effect of amitriptyline on RMP, APA, APD<sub>50</sub> and APD<sub>80</sub> levels and the maximum rise and decay slopes of AP were recorded.</p>
</sec>
<sec id="section8-0960327112455670">
<title>Group 2 (three animals, 12 cells for each dose)</title>
<p>Atria were incubated with DPCPX (a selective adenosine A<sub>1</sub> antagonist, 100 μM) for 20 min before the administration of amitriptyline.<sup>
<xref ref-type="bibr" rid="bibr4-0960327112455670">4</xref>
</sup> Following the incubation period, amitriptyline (1 μM, 10 μM and 50 μM) was administered. The effect of amitriptyline on RMP, APA, APD<sub>50</sub> and APD<sub>80</sub> levels and the maximum rise and decay slopes of AP were compared with the effects in the presence of DPCPX.</p>
</sec>
<sec id="section9-0960327112455670">
<title>Group 3 (three animals, 12 cells for each dose)</title>
<p>Atria were incubated with CSC (a selective A<sub>2a</sub> antagonist, 10 μM) for 20 min before the administration of amitriptyline.<sup>
<xref ref-type="bibr" rid="bibr4-0960327112455670">4</xref>
</sup> Following the incubation period, amitriptyline (1 μM, 10 μM and 50 μM) was administered. The effect of amitriptyline on RMP, APA, APD<sub>50</sub> and APD<sub>80</sub> levels and the maximum rise and decay slopes of AP were compared with the effects in the presence of CSC.</p>
<p>We did not test the effect of DMSO (solvent of adenosine receptor antagonists). The final concentration of DMSO were 0.1% and 1% in groups 2 and 3, respectively. In our previously studies, we tested the effects of 10% DMSO. It did not cause any change in the cardiovascular parameters.<sup>
<xref ref-type="bibr" rid="bibr3-0960327112455670">3</xref>
<xref ref-type="bibr" rid="bibr4-0960327112455670"/>–<xref ref-type="bibr" rid="bibr5-0960327112455670">5</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section10-0960327112455670">
<title>Statistical analysis</title>
<p>Changes in the same group were evaluated by Student’s <italic>t</italic> test for paired data. To analyze the differences among groups, analysis of variance and for multiple comparison Tukey’s post hoc test were performed (GraphPad Instat, GraphPad Software, La Jolla, California, USA). All data were expressed as mean ± SEM. <italic>p</italic> &lt; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="section11-0960327112455670">
<title>Results</title>
<sec id="section12-0960327112455670">
<title>The electrophysiological effects of amitriptyline on rat atrium</title>
<p>Amitriptyline did not alter RMP and APA in the rat atria; however, 50 μM amitriptyline significantly prolonged the APD<sub>50</sub> and APD<sub>80</sub> when compared with control values (from 11.78 ± 0.92 ms to 33.21 ± 1.81 ms, <italic>p</italic> &lt; 0.001; from 21.50 ± 1.79 ms to 62.28 ± 2.49 ms, <italic>p</italic> &lt; 0.0001, respectively; <xref ref-type="table" rid="table1-0960327112455670">Table 1</xref>). The maximum rise slope of AP was reduced in a dose-dependent manner with all three concentrations of amitriptyline (from 9.25 ± 0.47 V/s to 4.89 ± 0.65 V/s, 2.67 ± 0.29 V/s and 1.48 ± 0.27 V/s, <italic>p</italic> &lt; 0.0001, <italic>p</italic> &lt; 0.0001 and <italic>p</italic> &lt; 0.0001, respectively; <xref ref-type="table" rid="table1-0960327112455670">Table 1</xref>). Amitriptyline produced a significant reduction on the maximum decay slope of AP only at the highest (50 μM) concentration (from −0.53 ± 0.03 V/s to −0.11 ± 0.01 V/s, <italic>p</italic> &lt; 0.01; <xref ref-type="table" rid="table1-0960327112455670">Table 1</xref>).</p>
<table-wrap id="table1-0960327112455670" position="float">
<label>Table 1.</label>
<caption>
<p>Atrial action potential characteristics after amitriptyline administration with or without selective adenosine receptor antagonists</p>
</caption>
<graphic alternate-form-of="table1-0960327112455670" xlink:href="10.1177_0960327112455670-table1.tif"/>
<table>
<thead>
<tr>
<th>Groups</th>
<th>RMP (mV)</th>
<th>APA (mV)</th>
<th>APD<sub>50</sub> (ms)</th>
<th>APD<sub>80</sub> (ms)</th>
<th>Maximum rise slope of AP (V/s)</th>
<th>Maximum decay slope of AP (V/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>−75.96 ± 0.54</td>
<td>85.12 ± 0.59</td>
<td>11.78 ± 0.92</td>
<td>21.50 ± 1.79</td>
<td>9.25 ± 0.47</td>
<td>−0.53 ± 0.03</td>
</tr>
<tr>
<td colspan="7">Amitriptyline</td>
</tr>
<tr>
<td> Amit 1 μM</td>
<td>−77.75 ± 1.17</td>
<td>85.80 ± 1.22</td>
<td>10.98 ± 1. 01</td>
<td>22.98 ± 2.20</td>
<td>4.89 ± 0.65<sup>a</sup>
</td>
<td>−0.37 ± 0.03</td>
</tr>
<tr>
<td> Amit 10 μM</td>
<td>−77.46 ± 1.79</td>
<td>85. 01± 1.86</td>
<td>13.52 ± 1.23</td>
<td>26.20 ± 2.78</td>
<td>2.67 ± 0.29<sup>a</sup>
</td>
<td>−0.35 ± 0.04</td>
</tr>
<tr>
<td> Amit 50 μM</td>
<td>−78.22 ± 2.06</td>
<td>85.38 ± 2.19</td>
<td>33.21 ± 1.81<sup>b</sup>
</td>
<td>62.28 ± 2.49<sup>a</sup>
</td>
<td>1.48 ± 0.27<sup>a</sup>
</td>
<td>−0.11 ± 0.01<sup>c</sup>
</td>
</tr>
<tr>
<td colspan="7">100 μM DPCPX + Amit</td>
</tr>
<tr>
<td> DPCPX</td>
<td>−74.64 ± 0.83</td>
<td>83.76 ± 0.94</td>
<td>11.93 ± 1.51</td>
<td>21.10 ± 2.62</td>
<td>9.29 ± 0.67</td>
<td>−0.54 ± 0.05</td>
</tr>
<tr>
<td> DPCPX + Amit 1 μM</td>
<td>− 76.92 ± 0.93</td>
<td>85.96 ± 1.02</td>
<td>11.56 ± 0.98</td>
<td>22.06 ± 1.86</td>
<td>7.62 ± 0.84</td>
<td>−0.47 ± 0.04</td>
</tr>
<tr>
<td> DPCPX + Amit 10 μM </td>
<td>−76.91 ± 0.63</td>
<td>85.42 ± 0.67</td>
<td>15.08 ± 1.39</td>
<td>30.89 ± 2.56</td>
<td>4.00 ± 0.49<sup>a</sup>
</td>
<td>−0.29 ± 0.02<sup>d</sup>
</td>
</tr>
<tr>
<td> DPCPX + Amit 50 μM</td>
<td>−78.43 ± 1.59</td>
<td>86.40 ± 1.61</td>
<td>16.65 ± 1.75</td>
<td>32.76 ± 3.11</td>
<td>3.28 ± 0.46<sup>a</sup>
</td>
<td>−0.29 ± 0.03<sup>d</sup>
</td>
</tr>
<tr>
<td colspan="7">10 μM CSC + Amit</td>
</tr>
<tr>
<td> CSC</td>
<td>−75.46 ± 0.90</td>
<td>84.58 ± 0.99</td>
<td>14.17 ± 1.23</td>
<td>26.43 ± 3.16</td>
<td>8.35 ± 0.97</td>
<td>−0.41 ± 0.05</td>
</tr>
<tr>
<td> CSC + Amit 1 μM</td>
<td>−76.13 ± 0.73</td>
<td>84.76 ± 0.79</td>
<td>11.97 ± 0.68</td>
<td>21.91 ± 1.59</td>
<td>5.65 ± 0.68</td>
<td>−0.41 ± 0.02</td>
</tr>
<tr>
<td> CSC + Amit 10 μM</td>
<td>−74.67 ± 1.10<sup>d</sup>
</td>
<td>83.14 ± 1.25<sup>d</sup>
</td>
<td>14.40 ± 1.29</td>
<td>32.69 ± 3.33</td>
<td>5.56 ± 0.68<sup>c</sup>
</td>
<td>−0.29 ± 0.04</td>
</tr>
<tr>
<td> CSC + Amit 50 μM</td>
<td>−74.61 ± 1.92</td>
<td>82.61 ± 1.97</td>
<td>22.11 ± 1.13<sup>c</sup>
</td>
<td>52.00 ± 3.31</td>
<td>1.69 ± 0.09<sup>d</sup>
</td>
<td>−0.13 ± 0.01</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0960327112455670">
<p>Amit: amitriptyline; DPCPX: 8-cyclopentyl-1,3-dipropylxanthine, selective adenosine A<sub>1</sub> antagonist; CSC: 8-(3-chlorostyryl) caffeine, selective A<sub>2a</sub> antagonist; RMP: resting membrane potential; APA: action potential (AP) amplitude; APD<sub>50</sub> and APD<sub>80</sub>: action potential duration at 50 and 80% of repolarization levels.</p>
</fn>
<fn id="table-fn2-0960327112455670">
<p>
<sup>a</sup>
<italic>p</italic> &lt; 0.0001 versus control.</p>
</fn>
<fn id="table-fn3-0960327112455670">
<p>
<sup>b</sup>
<italic>p</italic> &lt; 0.001 versus control.</p>
</fn>
<fn id="table-fn4-0960327112455670">
<p>
<sup>c</sup>
<italic>p</italic> &lt; 0.01 versus control.</p>
</fn>
<fn id="table-fn5-0960327112455670">
<p>
<sup>d</sup>
<italic>p</italic> &lt; 0.05 versus control.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section13-0960327112455670">
<title>The electrophysiological effects of amitriptyline on rat atrium after DPCPX (10<sup>−</sup>
<sup>4</sup> M) incubation</title>
<p>After 20-min incubation with DPCPX, amitriptyline had no effect on the RMP, APA, APD<sub>50</sub> or APD<sub>80</sub>. When compared with control values, amitriptyline produced a dose-dependent reduction in both the maximum rise and decay slopes of AP at 10 μM and 50 μM, but there was no significant effect at 1 μM (from 9.25 ± 0.47 V/s to 4.00 ± 0.49 V/s and 3.28 ± 0.46 V/s, <italic>p</italic> &lt; 0.0001 and <italic>p</italic> &lt; 0.0001, respectively, from −0.53 ± 0. 03 V/s to −0.29 ± 0.02 V/s and −0.29 ± 0.03 V/s, <italic>p</italic> &lt; 0.05 and <italic>p</italic> &lt; 0.05, respectively; <xref ref-type="table" rid="table1-0960327112455670">Table 1</xref>).</p>
</sec>
<sec id="section14-0960327112455670">
<title>The electrophysiological effects of amitriptyline on rat atrium after CSC (10<sup>−</sup>
<sup>5</sup> M) incubation</title>
<p>After 20-min incubation with CSC, amitriptyline produced a minor reduction in the RMP and APA at 10 μM (from −75.96 ± 0.54 mV to −74.67 ± 1.10 mV, <italic>p</italic> &lt; 0.05; from 85.12 ± 0.59 mV to 83.14 ± 1.25 mV, <italic>p</italic> &lt; 0.05, respectively; <xref ref-type="table" rid="table1-0960327112455670">Table 1</xref>). The amitriptyline (50 μM) significantly prolonged the APD<sub>50</sub> when compared with control values (from 11.78 ± 0.92 ms to 22.11 ± 1.13 ms, <italic>p</italic> &lt; 0.01; <xref ref-type="table" rid="table1-0960327112455670">Table 1</xref>). When compared with control values, amitriptyline (10 μM and 50 μM) produced a significant reduction in the maximum rise slope of AP (from 9.25 ± 0.47 V/s to 5.56 ± 0.68 V/s and 1.69 ± 0.09 V/s, <italic>p</italic> &lt; 0.01 and <italic>p</italic> &lt; 0.05, respectively; <xref ref-type="table" rid="table1-0960327112455670">Table 1</xref>). </p>
<p>When the difference was compared between the groups, DPCPX significantly decreased the amitriptyline (50 μM)-induced prolongation of APD<sub>50</sub> and APD<sub>80</sub> (from 33.21 ± 1.81 ms to 16.65 ± 1.75 ms, <italic>p</italic> &lt; 0.001; from 62.28 ± 2.49 ms to 32.76 ± 3.11 ms, <italic>p</italic> &lt; 0.001, respectively; <xref ref-type="fig" rid="fig1-0960327112455670">Figures 1</xref> and <xref ref-type="fig" rid="fig2-0960327112455670">2</xref>). DPCPX significantly prevented the effects of amitriptyline (1 μM and 50 μM) on the maximum rise slope of AP (<italic>p</italic> &lt; 0.05 and <italic>p</italic> &lt; 0.05, <xref ref-type="fig" rid="fig3-0960327112455670">Figure 3</xref>). DPCPX significantly prevented the amitriptyline (50 μM)-induced reduction in the maximum decay slope of AP (<italic>p</italic> &lt; 0.001, <xref ref-type="fig" rid="fig4-0960327112455670">Figure 4</xref>). After CSC pretreatment, amitriptyline (10 μM)-induced reduction in the maximum rise slope of AP abolished (<italic>p</italic> &lt; 0.01, <xref ref-type="fig" rid="fig3-0960327112455670">Figure 3</xref>).</p>
<fig id="fig1-0960327112455670" position="float">
<label>Figure 1.</label>
<caption>
<p>The effects of amitriptyline administration on the action potential duration at 50% of repolarization (APD<sub>50</sub>) with or without selective adenosine receptor (three animals, 12 cells for each dose). DPCPX: 8-cyclopentyl-1,3-dipropylxanthine, a selective adenosine A<sub>1</sub> antagonist (100 μM); CSC: 8-(3-chlorostyryl) caffeine, a selective A<sub>2a</sub> antagonist (10 μM). <sup>###</sup>
<italic>p</italic> &lt; 0.001 versus control; ***<italic>p</italic> &lt; 0.001 versus amitriptyline (50 μM).</p>
</caption>
<graphic xlink:href="10.1177_0960327112455670-fig1.tif"/>
</fig>
<fig id="fig2-0960327112455670" position="float">
<label>Figure 2.</label>
<caption>
<p>The effects of amitriptyline administration on the action potential duration at 80% of repolarization (APD<sub>80</sub>) with or without selective adenosine receptor antagonists (three animals, 12 cells for each dose). DPCPX: 8-cyclopentyl-1,3-dipropylxanthine, a selective adenosine A<sub>1</sub> antagonist (100 μM); CSC: 8-(3-chlorostyryl) caffeine, a selective A<sub>2a</sub> antagonist (10 μM). <sup>####</sup>
<italic>p</italic> &lt; 0.0001 versus control; ***<italic>p</italic> &lt; 0.001 versus amitriptyline (50 μM).</p>
</caption>
<graphic xlink:href="10.1177_0960327112455670-fig2.tif"/>
</fig>
<fig id="fig3-0960327112455670" position="float">
<label>Figure 3.</label>
<caption>
<p>The effects of amitriptyline administration on the maximum rise slope of action potential with or without selective adenosine receptor antagonists (three animals, 12 cells for each dose). DPCPX: 8-cyclopentyl-1,3-dipropylxanthine, a selective adenosine A<sub>1</sub> antagonist (100 μM); CSC: 8-(3-chlorostyryl) caffeine, a selective A<sub>2a</sub> antagonist (10 μM). <sup>###</sup>
<sup>#</sup>
<italic>p</italic> &lt; 0.0001 versus control; <sup>†</sup>
<italic>p</italic> &lt; 0.05 versus amitriptyline (1 μM); **<italic>p</italic> &lt; 0.01 versus amitriptyline (10 μM); <sup>δ</sup>
<italic>p</italic> &lt; 0.05 versus amitriptyline (50 μM).</p>
</caption>
<graphic xlink:href="10.1177_0960327112455670-fig3.tif"/>
</fig>
<fig id="fig4-0960327112455670" position="float">
<label>Figure 4.</label>
<caption>
<p>The effects of amitriptyline administration on the maximum decay slope of action potential with or without selective adenosine receptor antagonists (three animals, 12 cells for each dose). DPCPX: 8-cyclopentyl-1,3-dipropylxanthine, a selective adenosine A<sub>1</sub> antagonist (100 μM); CSC: 8-(3-chlorostyryl) caffeine, a selective A<sub>2a</sub> antagonist (10 μM). <sup>##</sup>
<italic>p</italic> &lt; 0.01 versus control. ***<italic>p</italic> &lt; 0.001 versus amitriptyline (50 μM).</p>
</caption>
<graphic xlink:href="10.1177_0960327112455670-fig4.tif"/>
</fig>
</sec>
</sec>
<sec id="section15-0960327112455670">
<title>Discussion</title>
<p>Our study revealed the role of the adenosine receptors in cardiac conduction abnormalities induced by amitriptyline in isolated rat atria. Our major findings are as follows: (1) Amitriptyline (50 μM) administration prolonged APD<sub>50</sub> and APD<sub>80</sub> without altering RMP, APA. The maximum rise slope of AP was reduced in a concentration-dependent manner by amitriptyline. Amitriptyline produced a reduction in the maximum decay slope of AP only at 50 μM concentration. (2) DPCPX (a selective adenosine A<sub>1</sub> receptor antagonist) significantly decreased the amitriptyline (50 μM)-induced APD<sub>50</sub> and APD<sub>80</sub> prolongation. DPCPX significantly prevented the effects of amitriptyline (1 μM and 50 μM) on the maximum rise slope of AP. DPCPX also blocked the amitriptyline (50 μM)-induced reduction on the maximum decay slope of AP. CSC (a selective adenosine A<sub>2a</sub> receptor antagonist) significantly prevented the amitriptyline (10 μM)-induced reduction in the maximum rise slope of AP.</p>
<p>In our study, amitriptyline administration reduced the maximum rise slope of AP without altering RMP and APA. The reduction in the maxium rate of rise slope of AP supports the concept of potent sodium channel blockade by amitriptyline in rat atria. Some studies demonstrated that amitriptyline inhibited sodium channels.<sup>
<xref ref-type="bibr" rid="bibr9-0960327112455670">9</xref>
<xref ref-type="bibr" rid="bibr10-0960327112455670"/>
<xref ref-type="bibr" rid="bibr11-0960327112455670"/>
<xref ref-type="bibr" rid="bibr12-0960327112455670"/>
<xref ref-type="bibr" rid="bibr13-0960327112455670"/>–<xref ref-type="bibr" rid="bibr14-0960327112455670">14</xref>
</sup> In electrophysiological studies, tricylic antidepressants such as imipramine, clomipramine, amitriptyline, desipramine, dibenzepin, lofepramine and amoxapine were demonstrated to reduce the maximum velocity of depolarization (<italic>V</italic>
<sub>max</sub>) of the AP, an indirect index of the fast inward sodium current, (<italic>I</italic>
<sub>Na</sub>).<sup>
<xref ref-type="bibr" rid="bibr15-0960327112455670">15</xref>
</sup> Sasyniuk et al. reported that amitriptyline significantly depressed APA and APD as well as <italic>V</italic>
<sub>max</sub>.<sup>
<xref ref-type="bibr" rid="bibr9-0960327112455670">9</xref>
</sup>
</p>
<p>In our study, amitriptyline (50 μM) prolonged the APD<sub>50</sub> and APD<sub>80</sub> levels and produced a significant reduction in the maximum decay slope of AP. These findings imply that amitriptyline may also have potassium channel blocking actions. The transient outward K<sup>+</sup> current <italic>I</italic>
<sub>to</sub> is responsible for the initial rapid phase of AP repolarization. Several antidepressants with different chemical structures such as imipramine, amitriptyline, mianserine, maprotiline and trazodone block <italic>I</italic>
<sub>to</sub>.<sup>
<xref ref-type="bibr" rid="bibr14-0960327112455670">14</xref>,<xref ref-type="bibr" rid="bibr16-0960327112455670">16</xref>
</sup> Thus, the reduction in <italic>I</italic>
<sub>to</sub> could explain the prolongation of the APD. Jo et al. showed that amitriptyline blocked HERG (<italic>human ether a-go-go-related gene</italic>), the molecular equivalent of rapidly activating delayed rectifier K<sup>+</sup> current (<italic>I</italic>
<sub>Kr</sub>), which is one of the most important K<sup>+</sup> current in the repolarization of cardiac AP. However, amitriptyline blocked <italic>I</italic>
<sub>Kr</sub> rather than <italic>I</italic>
<sub>to</sub> in their experimental conditions. It has been suggested that amitriptyline may prolong APD primarily by blocking <italic>I</italic>
<sub>Kr</sub> rather than blocking <italic>I</italic>
<sub>to</sub>.<sup>
<xref ref-type="bibr" rid="bibr17-0960327112455670">17</xref>
</sup> Kobayashi et al. demonstrated that all of the tricylic antidepressants tested that desipramine, imipramine, amitriptyline, nortriptyline and clomipramine inhibited G protein-activated inwardly rectifying K<sup>+</sup> channels at micromolar concentrations.<sup>
<xref ref-type="bibr" rid="bibr18-0960327112455670">18</xref>
</sup>
</p>
<p>In our study, the amitriptyline-induced electrophysiological changes were prevented by DPCPX in isolated rat atria. DPCPX decreased the amitriptyline (50 μM)-induced prolongation of APD<sub>50</sub> and APD<sub>80</sub> and prevented the effects of amitriptyline (1 μM and 50 μM) on the maximum rate of rise slope of AP. DPCPX significantly prevented the amitriptyline (50 μM)-induced reduction in the maximum decay slope of AP. These results suggest that adenosine A<sub>1</sub> receptor stimulation may contribute to electrophysiological effects of amitriptyline. The results of our study are comparable with our previous studies.<sup>
<xref ref-type="bibr" rid="bibr3-0960327112455670">3</xref>
</sup> Kalkan et al. showed that hypotension and QRS prolongation by amitriptyline poisoning in rats were reverted by selective adenosine A<sub>1</sub> and A<sub>2a</sub> receptor antagonists (DPCPX and CSC, respectively).<sup>
<xref ref-type="bibr" rid="bibr3-0960327112455670">3</xref>
<xref ref-type="bibr" rid="bibr4-0960327112455670"/>–<xref ref-type="bibr" rid="bibr5-0960327112455670">5</xref>
</sup> Furthermore, in another study, it was found that the QRS prolongation developed by amitriptyline was diminished by specific adenosine A<sub>1</sub> receptor antagonist (DPCPX).<sup>
<xref ref-type="bibr" rid="bibr4-0960327112455670">4</xref>
</sup> In an isolated rat heart study, Akgun Arici et al. suggested that adenosine A<sub>1</sub> receptor stimulation that causes β-adrenergic receptor (β-AR) blockade may have a role in amitriptyline-induced QRS prolongation. An adenosine A<sub>1</sub> receptor antagonist, DPCPX, might prevent the inhibition of β-AR-mediated sodium current enhancement that results in shortening of QRS duration.<sup>
<xref ref-type="bibr" rid="bibr5-0960327112455670">5</xref>
</sup>
</p>
<p>Adenosine A<sub>1</sub> receptors, located in atrial and ventricular myocardium and sinoatrial and AV node, inhibit the activity of adenylyl cyclase enzyme.<sup>
<xref ref-type="bibr" rid="bibr19-0960327112455670">19</xref>
<xref ref-type="bibr" rid="bibr20-0960327112455670"/>–<xref ref-type="bibr" rid="bibr21-0960327112455670">21</xref>
</sup> Adenosine A<sub>1</sub> receptor-mediated actions in the heart are both cAMP-independent (direct effects) and cAMP-dependent (indirect or anti-adrenergic effects).<sup>
<xref ref-type="bibr" rid="bibr6-0960327112455670">6</xref>,<xref ref-type="bibr" rid="bibr21-0960327112455670">21</xref>
</sup> Adenosine produces a negative inotropic effect in atrial myocardium.<sup>
<xref ref-type="bibr" rid="bibr7-0960327112455670">7</xref>,<xref ref-type="bibr" rid="bibr21-0960327112455670">21</xref>
</sup> Two distinct mechanisms account for this effect. Under basal conditions, adenosine shortens the duration of AP and decreases contractility.<sup>
<xref ref-type="bibr" rid="bibr7-0960327112455670">7</xref>
</sup> This action is mediated by the adenosine-activated potasium acetylcholine (K<sub>ACh</sub>) channel effector system.<sup>
<xref ref-type="bibr" rid="bibr7-0960327112455670">7</xref>
<xref ref-type="bibr" rid="bibr8-0960327112455670"/>
<xref ref-type="bibr" rid="bibr9-0960327112455670"/>
<xref ref-type="bibr" rid="bibr10-0960327112455670"/>
<xref ref-type="bibr" rid="bibr11-0960327112455670"/>
<xref ref-type="bibr" rid="bibr12-0960327112455670"/>
<xref ref-type="bibr" rid="bibr13-0960327112455670"/>
<xref ref-type="bibr" rid="bibr14-0960327112455670"/>
<xref ref-type="bibr" rid="bibr15-0960327112455670"/>
<xref ref-type="bibr" rid="bibr16-0960327112455670"/>
<xref ref-type="bibr" rid="bibr17-0960327112455670"/>
<xref ref-type="bibr" rid="bibr18-0960327112455670"/>
<xref ref-type="bibr" rid="bibr19-0960327112455670"/>
<xref ref-type="bibr" rid="bibr20-0960327112455670"/>
<xref ref-type="bibr" rid="bibr21-0960327112455670"/>–<xref ref-type="bibr" rid="bibr22-0960327112455670">22</xref>
</sup> With enhanced adrenergic activity, adenosine attenuates both catecholamine-activated outward <italic>I</italic>
<sub>K</sub> and inward <italic>I</italic>
<sub>Ca</sub>, presumably by inhibition of phosphorylation of these channels, because adenosine inhibits adenylate cyclase activity and decrease the generation of cAMP.<sup>
<xref ref-type="bibr" rid="bibr7-0960327112455670">7</xref>
</sup> Adenosine presents antiadrenergic efficiency over delayed rectifier potassium (<italic>I</italic>
<sub>K</sub>) and chloride (<italic>I</italic>
<sub>Cl</sub>) currents and cAMP-dependent mechanism with <sc>l</sc>-type Ca<sup>+2</sup> channel current (<italic>I</italic>
<sub>CaL</sub>) in both supraventricular and ventricular tissues. While shortening is observed in ventricular AP by inhibition of <italic>I</italic>
<sub>CaL</sub> current-dependent catecholamine, prolongation is realized in AP with inhibition of <italic>I</italic>
<sub>K</sub> and <italic>I</italic>
<sub>Cl</sub> currents related to catecholamine.<sup>
<xref ref-type="bibr" rid="bibr6-0960327112455670">6</xref>,<xref ref-type="bibr" rid="bibr23-0960327112455670">23</xref>
</sup> The cardiac sodium channels and the delayed outward potassium channels are also regulated by intracellular cAMP-dependent protein kinase.<sup>
<xref ref-type="bibr" rid="bibr7-0960327112455670">7</xref>
</sup> Similar antagonistic regulation by adenosine may also exist for these channels.</p>
<p>Amitriptyline-induced cardiac dysrhythmias can result from the direct quinidine-like effect on cardiac function combined with anticholinergic activity and noradrenaline accumulation in the synapses by blockade of the noradrenaline transporter.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112455670">1</xref>,<xref ref-type="bibr" rid="bibr24-0960327112455670">24</xref>
</sup> In our study, the selective adenosine A<sub>1</sub> receptor antagonist prevented the electrophysiological effects of amitriptyline on atrial AP. A<sub>1</sub> receptor stimulation may be responsible for the cardiovascular toxic effects such as prolongation of QRS duration and QT interval produced by amitriptyline. The results of this study suggest that a cAMP-dependent (indirect or antiadrenergic effect) pathways via A<sub>1</sub> receptor may play a role on the mechanisms underlying electrophysiological changes induced by amitriptyline.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn1-0960327112455670">
<label>Authors’ Note</label>
<p>This study was presented as poster at Turkish Pharmacology Society, 21th National Congress of Pharmacology, 5th Clinical Pharmacology Symposium and 4th Clinical Toxicology Symposium, Eskisehir, Turkey, October 19–22, 2011.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0960327112455670">
<label>Funding</label>
<p>This study was supported by a grant from The Scientific and Technological Research Council of Turkey (TUBITAK, Grant Number: 107S251) and by the Turkish Academy of Sciences, in the framework of the Young Scientist Award Program (EA-TUBA-GEBIP/2001-2-11; to A.B.I.).</p>
</fn>
<fn fn-type="conflict" id="fn3-0960327112455670">
<label>Conflict of interest</label>
<p>The authors declared no conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0960327112455670">
<label>1</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Liebelt</surname>
<given-names>EL.</given-names>
</name>
</person-group> <article-title>Cyclic antidepressants</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Hoffman</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Howland</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>. (eds) <source>Goldfrank’s toxicology emergencies</source>. <publisher-loc>New York, USA</publisher-loc>: <publisher-name>McGraw-Hill Companies</publisher-name>, <year>2007</year>, pp. <fpage>608</fpage>–<lpage>615</lpage>.</citation>
</ref>
<ref id="bibr2-0960327112455670">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Unverir</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Atilla</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Karcioglu</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>A retrospective analysis of antidepressant poisonings in the emergency deparment: 11-year experience</article-title>. <source>Hum Exp Toxicol</source> <year>2006</year>; <volume>25</volume>: <fpage>605</fpage>–<lpage>612</lpage>.</citation>
</ref>
<ref id="bibr3-0960327112455670">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalkan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aygoren</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Akgun</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Do Adenosine receptors play a role in amitriptyline-induced cardiovascular toxicity in rats</article-title>. <source>J Toxicol Clin Toxicol</source> <year>2004</year>; <volume>42</volume>: <fpage>945</fpage>–<lpage>954</lpage>.</citation>
</ref>
<ref id="bibr4-0960327112455670">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akgun</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kalkan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hocaoglu</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of adenosine receptor antagonists on amitriptyline-induced QRS prolongation in isolated rat hearts</article-title>. <source>Clin Toxicol</source> <year>2008</year>; <volume>46</volume>: <fpage>677</fpage>–<lpage>685</lpage>.</citation>
</ref>
<ref id="bibr5-0960327112455670">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akgun Arici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kalkan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Demir</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Does adenosine A1 receptor stimulation causes QRS prolongation by blocking beta adrenergic receptors in amitriptyline poisoning?</article-title> <source>Toxicol Lett</source> <year>2009</year>; <volume>186</volume>: <fpage>130</fpage>–<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr6-0960327112455670">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lerman</surname>
<given-names>BB</given-names>
</name>
<name>
<surname>Belardinelli</surname>
<given-names>L.</given-names>
</name>
</person-group> <article-title>Cardiac electrophysiology of adenosine. Basic and clinical concepts</article-title>. <source>Circulation</source> <year>1991</year>; <volume>83</volume>: <fpage>1499</fpage>–<lpage>1509</lpage>.</citation>
</ref>
<ref id="bibr7-0960327112455670">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Kurachi</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Mechanisms of adenosine- mediated actions on cellular and clinical cardiac electrophysiology</article-title>. <source>Mayo Clin Proc</source> <year>1995</year>; <volume>70</volume>: <fpage>274</fpage>–<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr8-0960327112455670">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iskit</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Erkent</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Ertunc</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Glibenclamide attenuates the antiarrhymic effect of endotoxin with a mechanism not involving KATP channels</article-title>. <source>Vascul Pharmacol</source> <year>2007</year>; <volume>46</volume>: <fpage>129</fpage>–<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr9-0960327112455670">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasyniuk</surname>
<given-names>BI</given-names>
</name>
<name>
<surname>Jhamandas</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Mechanism of reversal of toxic effects of amitriptyline on cardiac Purkinje fibers by sodium bicarbonate</article-title>. <source>J Pharmacol Exp Ther</source> <year>1984</year>; <volume>231</volume>: <fpage>387</fpage>–<lpage>394</lpage>.</citation>
</ref>
<ref id="bibr10-0960327112455670">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barber</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Starmer</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>AO</given-names>
</name>
</person-group>. <article-title>Blockade of cardiac sodium channels by amitriptyline and diphenylhydantoin. Evidence for two use-dependent binding sites</article-title>. <source>Circ Res</source> <year>1991</year>; <volume>69</volume>: <fpage>677</fpage>–<lpage>696</lpage>.</citation>
</ref>
<ref id="bibr11-0960327112455670">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogata</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Narahashi</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Block of sodium channels by psychotropic drugs in single guinea-pig cardiac myocytes</article-title>. <source>Br J Pharmacol</source> <year>1989</year>; <volume>97</volume>: <fpage>905</fpage>–<lpage>913</lpage>.</citation>
</ref>
<ref id="bibr12-0960327112455670">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nau</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Seaver</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>GK</given-names>
</name>
</person-group>. <article-title>Block of human heart hH1 sodium channels by amitriptyline</article-title>. <source>J Pharmacol Exp Ther</source> <year>2000</year>; <volume>292</volume>: <fpage>1015</fpage>–<lpage>1023</lpage>.</citation>
</ref>
<ref id="bibr13-0960327112455670">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donovan</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Bakshi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Galbraith</surname>
<given-names>SE</given-names>
</name>
<etal/>
</person-group>. <article-title>Utility of frozen cell lines in medium throughput electrophysiology screening of hERG and NaV1.5 blockade</article-title>. <source>J Pharmacol Toxicol Methods</source> <year>2011</year>; <volume>64</volume>: <fpage>269</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr14-0960327112455670">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minoura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>DI Diego</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Barajas-Martínez</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Ionic and cellular mechanisms underlying the development of acquired brugada syndrome in patients treated with antidepressants</article-title>. <source>J Cardiovasc Electrophysiol</source> <year>2012</year>; <volume>23</volume>: <fpage>423</fpage>–<lpage>432</lpage>.</citation>
</ref>
<ref id="bibr15-0960327112455670">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pacher</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kecskemeti</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?</article-title> <source>Curr Pharm Des</source> <year>2004</year>; <volume>10</volume>: <fpage>2463</fpage>–<lpage>2475</lpage>.</citation>
</ref>
<ref id="bibr16-0960327112455670">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casis</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Sanchez-Chapula</surname>
<given-names>JA</given-names>
</name>
</person-group>. <article-title>Mechanism of block of cardiac transient outward K+ current (Ito) by antidepressant drugs</article-title>. <source>J Cardiovasc Pharmacol</source> <year>1998</year>; <volume>32</volume>: <fpage>527</fpage>–<lpage>534</lpage>.</citation>
</ref>
<ref id="bibr17-0960327112455670">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jo</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Youm</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>CO</given-names>
</name>
<etal/>
</person-group>. <article-title>Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline</article-title>. <source>Br J Pharmacol</source> <year>2000</year>; <volume>129</volume>: <fpage>1474</fpage>–<lpage>1480</lpage>.</citation>
</ref>
<ref id="bibr18-0960327112455670">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobayashi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Washiyama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs</article-title>. <source>Neuropsychopharmacology</source> <year>2004</year>; <volume>29</volume>: <fpage>1841</fpage>–<lpage>1851</lpage>.</citation>
</ref>
<ref id="bibr19-0960327112455670">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donato</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gelpi</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Adenosine and cardioprotection during reperfusion-overview</article-title>. <source>Mol Cell Biochem</source> <year>2003</year>; <volume>251</volume>: <fpage>153</fpage>–<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr20-0960327112455670">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hori</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kitakaze</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Adenosine, the heart, and coronary circulation</article-title>. <source>Hypertension</source> <year>1991</year>; <volume>18</volume>: <fpage>565</fpage>–<lpage>574</lpage>.</citation>
</ref>
<ref id="bibr21-0960327112455670">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mustafa</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pelleg</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology</article-title>. <source>Handb Exp Pharmacol</source> <year>2009</year>; <volume>193</volume>: <fpage>161</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr22-0960327112455670">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kienitz</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Littwitz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bender</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pott</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Remodeling of inward rectifying K(+) currents in rat atrial myocytes by overexpression of A(1)-adenosine receptors</article-title>. <source>Basic Res Cardiol</source> <year>2011</year>; <volume>106</volume>: <fpage>953</fpage>–<lpage>966</lpage>.</citation>
</ref>
<ref id="bibr23-0960327112455670">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belardinelli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shryock</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes</article-title>. <source>FASEB J</source> <year>1995</year>; <volume>9</volume>: <fpage>359</fpage>–<lpage>365</lpage>.</citation>
</ref>
<ref id="bibr24-0960327112455670">
<label>24</label>
<citation citation-type="other">
<comment>POISINDEX<sup>®</sup> System: Klasco RK (Ed): POISINDEX<sup>®</sup> System. Thomson Reuters, Greenwood Village, Colorado (Vol. 151 expires 3/2012).</comment>
</citation>
</ref>
</ref-list>
</back>
</article>